Skip to main content

Table 4 Association of change in cell counts (pre- to post-chemotherapy) and with post-chemotherapy frailty

From: The longitudinal relationship between immune cell profiles and frailty in patients with breast cancer receiving chemotherapy

Change in cell counts Post-chemotherapy frailty score: β (SE)
Neutrophils 0.026**      
(0.010)      
Lymphocytes   0.042     
  (0.032)     
Monocytes    0.019    
   (0.074)    
NLR     0.032***   
    (0.009)   
LMR      − 0.003*  
     (0.002)  
WBC       0.024**
      (0.009)
Baseline frailty 0.318*** 0.312*** 0.308*** 0.332*** 0.321*** 0.297***
(0.046) (0.047) (0.047) (0.047) (0.048) (0.045)
Age 50–64 0.216* 0.224* 0.215* 0.210* 0.211* 0.212*
(0.115) (0.115) (0.115) (0.116) (0.119) (0.111)
Age 65+ 0.312* 0.323** 0.301* 0.270 0.332** 0.240
(0.160) (0.161) (0.161) (0.164) (0.167) (0.156)
White (yes = 1) 0.104 0.145 0.083 0.091 0.143 0.036
(0.176) (0.177) (0.174) (0.179) (0.183) (0.169)
Married (yes = 1) − 0.331*** − 0.322*** − 0.328*** − 0.281** − 0.268** − 0.311***
(0.118) (0.120) (0.120) (0.121) (0.124) (0.116)
Some college or above = 1 0.152 0.136 0.113 0.204 0.143 0.185
(0.123) (0.123) (0.123) (0.125) (0.127) (0.118)
Constant 1.444*** 1.462*** 1.520*** 1.296*** 1.350*** 1.564***
(0.230) (0.233) (0.228) (0.236) (0.239) (0.223)
Observations 459 459 461 439 427 508
R-squared 0.135 0.123 0.115 0.147 0.126 0.115
  1. Linear regression models were used to evaluate the association between cell counts and frailty, controlling for age (below 50, 50–64 versus ≥ 65 years), race (white versus non-white), marital status (married/long term relationship versus others), and education (≥ some college versus ≤ high school)
  2. NLR neutrophil to lymphocyte ratio, LMR lymphocyte to monocyte ratio
  3. *Significant at 10%; **significant at 5%; ***significant at 1%